Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer

Summary

A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo). The efficacy was evaluated every six weeks.Follow-up continued until disease progression or death.

Timeline

Start

2011-05

Primary completion

2012-12

Completion

2013-04

Drugs

Indications